Luca Lazzari

TL;DR: In this article, the authors studied EGFR blockade in colorectal cancer to assess whether tissue and liquid biopsies can be integrated with radiological imaging to monitor the impact of individual oncogenic alterations on lesion-specific responses.

TL;DR: Proof of principle that analyses of xenopatients and liquid biopsies allow the identification of drug resistance mechanisms in parallel with clinical treatment of an individual patient is provided and can be immediately exploited to design next-generation TRKA inhibitors.

TL;DR: ALK, ROS1, and NTRK rearrangements define a new rare subtype of mCRC with extremely poor prognosis, and four evaluable patients with rearranged patients showed primary resistance to anti-epidermal growth factor receptor agents.

TL;DR: The studies from Bettegowda and Misale and their colleagues show the effectiveness of analyzing circulating DNA from a variety of tumors and highlight the potential applications of this technology for early detection, monitoring resistance, and devising treatment plans to overcome resistance.

TL;DR: Colorectal tumors evade EGFR blockade by constitutive activation of downstream signaling effectors and through mutations affecting receptor–antibody binding through mechanisms of resistance to cetuximab, which may occur concomitantly.